Slowed cell division causes microcephaly
Scientists from UNIGE demonstrate how the mutation of a single gene can slow down cell division and lead to an abnormally small brain.
2021-06-17
(Press-News.org) The birth of a human being requires billions of cell divisions to go from a fertilised egg to a baby. At each of these divisions, the genetic material of the mother cell duplicates itself to be equally distributed between the two new cells. In primary microcephaly, a rare but serious genetic disease, the ballet of cell division is dysregulated, preventing proper brain development. Scientists from the University of Geneva (UNIGE), in collaboration with Chinese scientists, have demonstrated how the mutation of a single protein, WDR62, prevents the proper formation of the cable network responsible for separating genetic material into two. As cell division is then slowed down, the brain does not have time to build itself completely. These results, to be read in the Journal of Cell Biology, shed new light on cell division, a phenomenon also involved in cancer development.
Cell division is an essential mechanism for the development of any new being. It is precisely regulated and requires coordination and control. To this end, cables called "microtubules" allow the genetic material packed in chromosomes to be distributed equally between the two daughter cells. "These microtubules continually assemble and disassemble to reach their proper size at any moment", explains Patrick Meraldi, professor in the Department of Cell Physiology and Metabolism at UNIGE Faculty of medicine and coordinator of the Translational Research Centre in Onco-haematology (CRTOH), who led this work. "To regulate their size, the cell uses a protein, katanin (from the Japanese katana for sword) in charge of cutting microtubules to the right length."
A minor mutation with severe consequences
A mutation of any of the genes involved in cell division is enough to cause an abnormally small brain and serious neuronal problems, thus strongly limiting the autonomy of affected individuals. Primary microcephaly is often linked to consanguineous unions and affects between 1 in 30,000 and 1 in 250,000 people, depending on the region of the world.
But how can a single mutation have such serious consequences? And why, if the mutated gene is so important, is brain development the only to be affected? The first clues to answering these questions came a few years ago, when scientists discovered that the most frequently mutated gene in microcephaly, ASPM, is involved in the location and function of katanin, the molecular sword responsible for cutting microtubules. "But was this the core mechanism of microcephaly or just specific to this mutation?" asked Amanda Guerreiro, postdoctoral fellow in Patrick Meraldi's laboratory and first author of the study.
Katanin, an essential molecular sword
In vitro experiments with cell lines revealed that the second most common gene involved in microcephaly, WDR62 was, like ASPM, required for the localisation and function of katanin. Similarly, scientists observed that if katanin is not in the right place at the right time, microtubules become too long. As space is limited, they are under compression and become S-shaped rather than straight and tensed. Consequently, when microtubules have to pull chromosomes to distribute them evenly in the two new cells, tension is not strong enough and some chromosomes lag behind others. A slight dysregulation in the mechanics of cell division is enough to slow down the distribution of chromosomes. Since this delay is considered by cells to be a serious failure, many will die. The death of too many cells would then result in the abnormally small size of the brain of people with primary microcephaly.
"Katanin seems to be the central mechanism of this developmental disease," says Patrick Meraldi. "However, the outcome of our work is much broader: it allows us to understand how cancer cells modify the system to divide endlessly and proliferate in the body."
INFORMATION:
ELSE PRESS RELEASES FROM THIS DATE:
2021-06-17
BOSTON - An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows. The findings have spurred investigators to open a clinical trial of the drug, novobiocin, for patients whose tumors carry the abnormality.
In a study in the journal Nature Cancer, the researchers found that in laboratory cell lines and tumor models novobiocin selectively killed tumor cells with abnormal BRCA1 or BRCA2 genes, which help repair damaged DNA. The drug was effective even in tumors resistant to agents known as PARP inhibitors, which have become a prime therapy for cancers with DNA-repair glitches.
"PARP inhibitors ...
2021-06-17
Ultrathin, flexible computer circuits have been an engineering goal for years, but technical hurdles have prevented the degree of miniaturization necessary to achieve high performance. Now, researchers at Stanford University have invented a manufacturing technique that yields flexible, atomically thin transistors less than 100 nanometers in length - several times smaller than previously possible. The technique is detailed in a paper published June 17 in Nature Electronics.
With the advance, said the researchers, so-called "flextronics" move closer to reality. Flexible electronics promise bendable, ...
2021-06-17
PHILADELPHIA-- The COVID-19 death rate for Black patients would be 10 percent lower if they had access to the same hospitals as white patients, a new study shows. Researchers from the Perelman School of Medicine at the University of Pennsylvania and OptumLabs, part of UnitedHealth Group, analyzed data from tens of thousands of hospitalized COVID-19 patients and found that Black patients died at higher rates than white patients. But the study, published today in JAMA Network Open, determined that didn't have to be the case if more Black patients were able to get care at different hospitals.
"Our study reveals that Black patients have worse outcomes largely because they tend to go to worse-performing hospitals," said the study's first author, David Asch, MD, ...
2021-06-17
What The Study Did: The findings of this study suggest that the increased mortality among Black patients hospitalized with COVID-19 is associated with the hospitals at which Black patients disproportionately received care.
Authors: David A. Asch, M.D., M.B.A., of the University of Pennsylvania in Philadelphia, is the the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2021.12842)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, ...
2021-06-17
What The Study Did: Researchers evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic (blood) cancers and COVID-19.
Authors: Jeremy L.Warner, M.D., M.S., of Vanderbilt University in Nashville, Tennessee, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2021.1799)
Editor's Note: The article includes conflict of interest and funding/support disclosures. Please ...
2021-06-17
What The Study Did: This study examined whether mandatory daily employee symptom data collection can be used as an early alert surveillance system to estimate COVID-19 hospitalizations in communities where employees live.
Authors: Steven Horng, M.D., M.MSc., of Beth Israel Deaconess Medical Center in Boston, is the the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2021.13782)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
INFORMATION:
Media advisory: The full study ...
2021-06-17
What The Study Did: In this survey study, COVID-19 was associated with large reductions in economic security among women at high risk of HIV infection in Kenya. However, shifts in sexual behavior may have temporarily decreased their risk of HIV infection.
Authors: Harsha Thirumurthy, Ph.D., of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, is the the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2021.13787)
Editor's Note: The article includes funding/support disclosures. Please see the article for additional information, including other authors, ...
2021-06-17
What The Study Did: Researchers estimated survival and other outcomes of very preterm infants in China discharged against medical advice from neonatal intensive care units before complete care can be provided compared with infants who receive full intensive care treatment.
Authors: Yun Cao, M.D., Ph.D., and Weili Yan, Ph.D., of Children's Hospital of Fudan University in Shanghai, China, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2021.13197)
Editor's Note: The article includes conflicts of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest ...
2021-06-17
The 'Xpert Ultra' molecular test has a greater capacity than its predecessor ('Xpert MTB/RIF') in detecting tuberculosis cases, either passively (i.e. people who attend the hospital with disease symptoms) or actively (searching for possible cases in the community among contacts of cases). This is the main conclusion of a study performed by ISGlobal, an institution supported by "la Caixa" Foundation, in collaboration with the Manhiça Health Research Centre (CISM), published in the European Respiratory Journal.
Tuberculosis (TB) is the leading cause of death by an infectious agent, worldwide. In 2019, 1.4 million people are estimated to have died and 10 million people fell sick from TB, although only 70% of the cases were diagnosed. ...
2021-06-17
Scientists have identified a new class of targeted cancer drugs that offer the potential to treat patients whose tumours have faulty copies of the BRCA cancer genes.
The drugs, known as POLQ inhibitors, specifically kill cancer cells with mutations in the BRCA genes while leaving healthy cells unharmed.
And crucially, they can kill cancer cells that have become resistant to PARP inhibitors - an existing treatment for patients with BRCA mutations.
Researchers are already planning to test the new drug class in upcoming clinical trials. If the trials are successful, POLQ inhibitors could enter the clinic as a new approach to treating a range of cancers with BRCA ...
LAST 30 PRESS RELEASES:
[Press-News.org] Slowed cell division causes microcephaly
Scientists from UNIGE demonstrate how the mutation of a single gene can slow down cell division and lead to an abnormally small brain.